Invitation to Roche’s Virtual AAN Investor Event
2026-03-27
 We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 22 April 2026, to highlight the new data from the Phase III FENhance1/2 study evaluating fenebrutinib vs. Aubagio in RMS, which will be presented at the American Academy of Neurology (AAN) forum from 18-22 April 2026. 17:00-18:00 CEST / 16:00-17:00 BST 8:00-9:00 PDT / 11:00-12:00 EDT Agenda Introduction Bruno Eschli, Head of Investor Relations Fenebrutinib development overview Alexandra Goodyear, Lifecycle Leader Fenebrutinib Ph III (FENhance 1/2) fenebrutinib vs. Aubagio in RMS Jiwon Oh, MD, PhD, FRCPC, Medical Director, Barlo Multiple Sclerosis Program, Associate Professor, Division of Neurology, St. Michael’s Hospital, University of Toronto, Staff Neurologist, St. Michael’s Hospital, Scientist, Keenan Research Centre of the Li Ka Shing Knowledge Institute Q&A The slides will be available for download at 16:00 CEST on the day of the event. > click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards, |
| Bruno Eschli Head of Investor Relations | Loren Kalm Head of Investor Relations, North America |
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.